Suggested remit - To appraise the clinical and cost effectiveness of rituximab within its marketing authorisation for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis.
Status Awaiting development
Decision None selected
Process STA pre-2018
ID number 1320

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
20 March 2018 - 19 April 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual